AMBU B logo

Ambu A/S Stock Price

CPSE:AMBU B Community·DKK 21.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

AMBU B Share Price Performance

DKK 82.60
-50.25 (-37.82%)
DKK 114.64
Fair Value
DKK 82.60
-50.25 (-37.82%)
28.0% undervalued intrinsic discount
DKK 114.64
Fair Value
Price DKK 82.60
AnalystConsensusTarget DKK 114.64
AnalystLowTarget DKK 78.00
AnalystHighTarget DKK 139.00

AMBU B Community Narratives

AnalystConsensusTarget·
Fair Value DKK 114.64 28.0% undervalued intrinsic discount

Expansion Of Single-use Endoscopy Will Improve Hospital Efficiency

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystLowTarget·
Fair Value DKK 78 5.9% overvalued intrinsic discount

Rising Costs, Stricter Rules And Rivals Will Limit Market Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value DKK 139 40.6% undervalued intrinsic discount

Aging Global Population And Healthcare Digitalization Will Expand Single-Use Endoscopy

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
DKK 78
5.9% overvalued intrinsic discount
Revenue
10.15% p.a.
Profit Margin
13.37%
Future PE
23.28x
Price in 2029
DKK 90.82
DKK 114.64
28.0% undervalued intrinsic discount
Revenue
10.72% p.a.
Profit Margin
14.24%
Future PE
31.04x
Price in 2029
DKK 133.19
DKK 139
40.6% undervalued intrinsic discount
Revenue
12.67% p.a.
Profit Margin
15.59%
Future PE
32.63x
Price in 2029
DKK 161.57

Trending Discussion

Updated Narratives

AMBU B logo

AMBU B: Higher Risk Premium And Margin Pressure Will Reshape Share Outlook

Fair Value: DKK 78 5.9% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AMBU B logo

AMBU B: Share Repurchases And Dividend Policy Will Support Future Upside

Fair Value: DKK 114.64 28.0% undervalued intrinsic discount
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AMBU B logo

AMBU B: Share Buybacks And Dividend Policy Will Support Future Upside

Fair Value: DKK 139 40.6% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with solid track record.

0 Risks
3 Rewards

Ambu A/S Key Details

DKK 6.1b

Revenue

DKK 2.4b

Cost of Revenue

DKK 3.7b

Gross Profit

DKK 3.1b

Other Expenses

DKK 544.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 06, 2026
2.05
60.07%
8.94%
0.2%
View Full Analysis

About AMBU B

Founded
1937
Employees
5200
CEO
Britt Jensen
WebsiteView website
www.ambu.com

Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also provides airway management and anaesthesia products, which include double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers emergency care and training products, such as extrication collars and ALS and BLS training manikins, as well as mobile workstations, IOMs, and patient monitoring and diagnostics devices. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.

Recent AMBU B News & Updates

Earnings Miss: Ambu A/S Missed EPS By 8.7% And Analysts Are Revising Their Forecasts

Feb 08
Earnings Miss: Ambu A/S Missed EPS By 8.7% And Analysts Are Revising Their Forecasts

Recent updates

No updates